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This study aims to investigate the eﬀects of two application frequencies of parathyroid hormone on the trochanteric region of
rat femur. Forty-three-month-old female Sprague-Dawley rats were divided into 4 groups (n = 10/group). Three groups were
ovariectomized, and8 weeks laterthey were administered thefollowingtreatments (5 weeks): soy-free diet (OVX),subcutaneously
injected PTH (0.040mg/kg) 5 days a week (PTH 5x/w), subcutaneously injected PTH (0.040mg/kg) every 2 days (PTH e2d),
and a sham group. The values of the biomechanical and histomorphometric parameters showed higher results in 5x/w animals
in comparison to the OVX and PTH 2ed groups. The ratio between bone diameter/marrow diameter (B.Dm/Ma.Dm) in
subtrochanteric cross sections did not show any signiﬁcant diﬀerences between PTH 5x/w and PTH e2d. The increased bone
formation rate was observed under PTH treatment in both groups mainly at the endosteal side. The endosteum seems here to
be one of the targets of PTH with an accelerate bone formation and a pronounced ﬁlling-in of intracortical cavities with higher
intensity for the PTH 5x/w in comparison to PTH e2d rats.
1.Introduction
In the last decade, the parathyroid hormone (PTH) has
become more important as a possible alternative for the
treatment ofpostmenopausal osteoporosis.Most ofthestud-
ies with PTH have focused mainly on the dose-dependent
eﬀects of this hormone or its combination with other drugs
[1–4]. Since researchers found that the intermittent substi-
tution of PTH, in contrast to its continuous application,
was able to prevent postmenopausal bone loss, the question
has been which application frequency would deliver the
best anabolic result [5]? The time interval between the
anabolic und catabolic eﬀects of intermittent application
of PTH (“anabolic window”) is the key to respond and
to understand such behavior of this hormone. In addition,
another unanswered question is how PTH aﬀects diﬀerent
skeletal sites like the wrist, proximal tibia, vertebral bodies
and, especially, proximal femur.
It is known that the trochanteric fracture of the femur
is one of the most common fracture types in menopausal
women. Therefore, investigations of the strength of this
skeletal site after treatment with antiosteoporotic agents
seem to be important and have a high clinical relevance
[6]. Such investigations, however, are rare because of the
diﬃculty in producing a reliable trochanteric fracture in
animal models [7].
The ovariectomized (OVX) rat is a well-proven animal
model for osteoporosis studies [8, 9]. There are many
similarities between the human and rat femur, both at the
microstructural and macrostructural levels [10, 11].2 Journal of Osteoporosis
In the present study, we investigated the region-speciﬁc
inﬂuence of two diﬀerent application frequencies of PTH on
femoral trochanteric strength of ovariectomized rats.
2.Materialsand Methods
2.1. Experimental Animals and Substances. The experi-
ments were carried out using forty-three-month-old female
Sprague-Dawley rats fed a standard diet ad libitum. The
animals were randomized by weight into four experimental
groups (n = 10 in each group): OVX soy-free group (OVX),
PTH group receiving 5x/w), PTH group receiving subcuta-
neousinjectionsof0.040mg/kgparathyroid hormone(1-34)
every2days(PTHe2d),andashamgroup.The experimental
procedures were approved by the local ethics commission
under German animal protection law (permission from
11.03.1998,AZ:509.42502/01-02.98.BezirkregierungBraun-
schweig).EightweeksafterbilateralOVX,westartedthedrug
treatments, which were continued for the next ﬁve weeks.
After ﬁve weeks of drug therapy, the rats were euthanized,
and both femurs were dissected free of soft tissue to be used
for biomechanical and histomorphometric tests.
During the treatment, the animals were subcutaneously
injectedwithfourﬂuorescentsubstances(Merck,Darmstadt,
Germany) to mark the process of bone formation, especially
in the cortical surface [12]. The following ﬂuorescent agents
injected were xylenol orange (90mg/kg) on day 13, calcein
green (10mg/kg) on day 18, alizarin red (30mg/kg) on day
24/26, and tetracycline (25mg/kg) on day 35. This agent
(tetracycline) was applicated 2 hours before euthanizing the
animals. It is well known that tetracyclines are able rapidly to
bind to new formatted bones immediately after application.
The resultsoftheﬂuorochrome labeling were analyzed in
cross sections of femurs 15mm distal from the femoral head
in the subtrochanteric region [6].
2.2. Biomechanical Test. The biomechanical test was per-
formed with our new breaking test as previously described
[13]. In a deepening (4mm diameter), the femoral head (left
femurs) was ﬁxed at proximal end of the breaking machine.
The femoral shaft was positioned between two rotable
cylinders. Force was applied with a ZWICK-testing machine,
type 145660 Z020/TND(Zwick/Roell,Ulm, Germany), from
thelateralsideofthebone(verticallytothetrochantertertius
in rat) to the greater (major) trochanter using a metallic
stamp.
The range of assessment was from 2N to 500N. During
the mechanical test, the bone had the possibility to slide
between the roller clamps. The force was applied until
the femur was broken in the trochanteric region. The
measured curve after breaking test fulﬁlled the load and
displacement during the test. The “slope” of our breaking
curve (load-displacement-curve) corresponds to the tangent
of the strength-strain-curve. This tangent demonstrates the
elasticity of each material. This means that in our study the
slope of the breaking curves shows the elasticity of the bones
(femurs). Load and displacement were recorded, and ulti-
mate maximal breaking strength (maximal load, Fmax (N))
and stiﬀness (elasticity, slope of the linear part of the curve,
N/mm) were calculated.
The measurement of yield point (yield load) of bone
is not easy. In the opinion of many researches, it is only
possible to measure the “yield area” and not “a point.” The
mean reason for this is the inhomogeneity of bone (consist
of mineral, organic material and many other elements and
water).
Using the curve of F(max) (maximal load) and the load
displacement, we can only measure the yield area.
T h ew o r ko fB r z o ’ s k ae ta l .c o n ﬁ r m e dt h ef a c tt h a ta f t e r
breaking the femoral neck they could see diﬀerent curves. In
their study, this fact made the measurement of yield load
of femoral neck more diﬃcult. Our previous experiments
could, however, show that the yield area also in our femurs
corresponds approximately to both standard deviations.
We deﬁned the yield point (load) as a decrease in
elasticity (stiﬀness) of more than twice the standard
deviation (SD) [14].
2.3. Radiography of Fractures. X-ray radiography (in the
anterior-posterior and lateral view) of all left femurs was
performed in the study (Figures 1(a) and 1(b)). For this, we
used a special Kodak-ﬁlm (Kodak SR type 45) and a Faxitron
ﬁne-focus cabinet X-ray system (model 43855A; Faxitron X-
ray System) with 40kV.
2.4. Cancellous and Cortical Bone Histomorphometry. The
left femurs were ﬁxed, after the biomechanical test, in 70%
ethanol for 2days (48hours), dehydrated through an alcohol
gradient, and at least embedded in methyl methacrylate gel.
Sagittal, sections (150µm thick) of the embedded proximal
femur were prepared using a microtome (Leica, Sawmi-
crotom 1600). The target region of embedded femur for
the histomorphometry analysis was the frame between the
epiphysealzoneandthefemoralintertrochanteric line(2mm
distally). These microradiographs of the femoral sections
were used to analyze the histomorphometric changes in the
trabecular surfaces (Figure 1(c)).
We used a digitizing morphometric system to measure
and analyze bone histomorphometric parameters. The sys-
tem consisted of a microscope (Leica-System MZ 7.5), a
digitizing pad coupled to a personal computer with an
additional morphometry program (Qwin software).
We measured trabecular area (Tb.Ar),the number oftra-
becularnodes(N.Nd),trabecularconnectivity(N.Nd/mm2),
and mean trabecular width (Tb.Wi) [15].
A problem is the very diﬃcult measurement of the
cortical changes at cortical surface in medial proximal
femoral neck. The proximal (medial) part of the femoral
neck in rats and other large animals seems not to be covered
by periosteal tissue. This is an important factor to consider,
especially when anabolic agents are tested with pronounced
periosteal stimulation. In contrast, the trochanteric region
contains acortical surface covered byasuﬃcient periosteum.
Furthermore, the trochanteric region has a high content of
trabecular net.Journal of Osteoporosis 3
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Figure 1: Radiographs of proximalratfemurs after breaking test. (a)Anterior-posterior view (ap-view) ofthe reversed trochanteric fracture
ofratfemur (type A3fracture according to AOclassiﬁcation).(b) Lateral view.(c) The ﬁgure showsthe microarchitecture (microradiograph
of sagittalsection) of proximal femur of Sprague-Dawley rat. Pleasenot et h ef r a c t u r el i n ea n dt h ec o n t e n to ft h et r a b e c u l a rb o n ei nt h i sa r e a .
B e c a u s em e a s u r a b l ec h a n g e si nt h ec o r t i c a la r e ao c c u r
ﬁrst long time after OVX, the real early changes of thickness
in this region remain diﬃcult to measure.
Wemeasured theratiobetweendiameteroffemoralbone
(B.Dm) and marrow diameter (Ma.Dm) in thecross sections
15mm distal of the capitis femoris (femoral head) in the
subtrochanteric area [6]. We assessed the B.Dm of the cross
sections in the midline of the cross sections (dorso-ventral-
axis) and on the same line as the Ma.Dm as previously
described (Figure 2). [6] It is here important to mention
that this area in rat is a region between major trochanter,
minor trochanter, and tertius trochanter. This means that
this part (in rat) belongs to “the trochanteric region”. The
further advantage of using the proximal femur (15mm distal
to the femoral head) is the opportunity to have a relatively
homogenous width of cortical surface and its independence
to the technical problems during providing suﬃcient cross
sections.
2.5. Serum Analysis for Bone Anabolic Markers. Blood sam-
ples (5mL) were collected from the sacriﬁced animals and
centrifuged at 3000g for 10 minutes. The serum was stored
at −20◦C until the electrochemiluminescence immunoassay
(ECLIA, Roche diagnostics, Mannheim, Germany) was per-
formed. The level of osteocalcin was measured in the serum.
A further marker of bone remodeling, alkaline phosphatase
(AP), was also quantitatively determined.
2.6. Ashing. To determine the amount of mineralized bone,
the right femurs were mineralized at 750◦Ca n dw e i g h e dt o
the nearest 10−5 g. The femurs were weighed (dry) before
a1
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Figure 2: Cortical bone analysis.The ﬁgure shows the trochanteric
cross section of proximal femur of Sprague-Dawley rat, cut 15mm
distal from the capitis femoris. We measured the bone diameter
(B.DM) and the marrow diameter (Ma.Dm) on the ventrodorsal
axis (the line perpendicular to the middle of the mediolateral axis)
of the cross section.
and after ashing. At the end of the experiment, the mineral
content of each bone was indicated as a percentage of the
total weight of the same femur (weight after ashing/weight
before ashing).
2.7. Statistics. The mean values of the diﬀerences between
the study groups in all of the comparative bioassays were
assessed using one-way ANOVA test with Tuckey kramer
post hoc test. (Prism TM 4.0, Graph Pad, San Diego, USA).
P values <. 05 were considered signiﬁcant.4 Journal of Osteoporosis
3.Results
3.1. Body Weight and Mineral Content. As demonstrated in
Table 1, there were no signiﬁcant diﬀerences in body weight
between the groups at the beginning of the study. At the end
of experiment, we observed a signiﬁcant weight gain in all
groups compared to the sham group (Table 1).
After ashing of the left femurs, both PTH 5x/w and PTH
e2d groups (49.54% and 48.30%, resp.) showed signiﬁcantly
highermineral contentandsimilar mineralcontentthan that
of the sham group compared to the OVX (45.80%) group.
Although the mean value in the PTH 5x/w rats was higher
than the PTH e2d animals, the diﬀerence in mineral content
wasnotstatisticallysigniﬁcant. Inaddition,theOVXanimals
clearly had less mineral content in comparison to the sham
(49.68%) rats.
3.2. Biomechanical Test. The mean values of maximal load
(Fmax), stiﬀness, and yield load (yL) showed higher results
after treatment with parathyroid hormone 5x/w (Fmax =
194.1N,stiﬀness = 347.6N/mm, yL = 134.6N)incompar-
ison to the e2d group (Fmax = 176.3N, stiﬀness =
250.9N/mm, yL = 110.3N). These results were statistically
signiﬁcant for stiﬀness. Concerning biomechanical parame-
ters,theresultsofthePTH5x/wanimals showed asigniﬁcant
improvement compared to the OVX rats, but there were
no signiﬁcant diﬀerences between the OVX group (Fmax =
169.3N, stiﬀness = 230.2N/mm, yL = 86.96N) and the
PTH e2d group.
Concerning stiﬀness and yield load, the sham animals
had higher results (Fmax = 187.0N,stiﬀness = 294.8N/mm,
yL = 120.6N)thanOVXrats(Table 1). Concerning biome-
chanical parameters, the results of the PTH 5x/w animals
showed a signiﬁcant improvement compared to the OVX
rats, but there were no signiﬁcant diﬀerences between the
OVX group (Fmax = 169.3N, stiﬀness = 230.2N/mm,
yL = 86.96N) and the PTH e2d group. The mean values of
maximal load (Fmax), stiﬀness, and yield load (yL) showed
higher results after treatment with parathyroid hormone
5x/w (Fmax = 194.1N, stiﬀness = 347.6N/mm, yL =
134.6N) in comparison to the e2d group (Fmax = 176.3N,
stiﬀness = 250.9N/mm, yL = 110.3N). These results were
statistically signiﬁcant for stiﬀness.
3.3. Serum Analysis. Serum osteocalcin levels diﬀered
between both PTH-treated groups (P<. 05) in com-
parison to the sham and OVX animals. There were no
signiﬁcant diﬀerences in serum OC levels between the PTH
5x/w (37.43ng/mL) and PTH e2d groups (32.55ng/mL).
In sham animals (14.59ng/mL), OC levels were lower
compared to OVX rats (17.83ng/mL), but the results were
not signiﬁcant. The concentration of AP in the PTH e2d
group (74.27ng/mL) was increased, but this result was
only signiﬁcant compared to the sham group (40.90ng/mL)
(Table 1).
3.4. Histomorphometry Analysis. Table 2 shows the results of
histomorphometric tests.
The number of trabecular nodes/mm2 (N.Nd/mm2 =
connectivity) was signiﬁcantly higher in sham (21.34) and
PTH e2d (19.10) groups compared to OVX rats (11.91).
Conversely, there were no signiﬁcant diﬀerences in connec-
tivity between the PTH 5x/w and PTH e2d groups. The
PTH 5x/wrats demonstrated betterresults concerningTb.Ar
and Tb.Wi in comparison to PTH e2d animals. However,
the only statistically signiﬁcant diﬀerence between the PTH
groups was for Tb.Wi. Both PTH-treated groups (5x/w and
e2d) presented improved results for Tb.Ar (81.54% versus
73.38%) and Tb.Wi (17.59 versus 14.65µm) compared to
OVX rats (Tb.Ar = 41.15%, Tb.Wi = 11.51µm). Concerning
Tb.Ar and Tb.Wi, the PTH 5x/w showed signiﬁcantly better
results than the sham group (Tb.Ar = 66.85%, Tb.Wi =
12.24µm).
To determine the changes in the cortical surface of the
femurs, we measured the diameters of subtrochanteric bone
cross sections (B.Dm) and the marrows (Ma.Dm) in the
ventro-dorsal axis in all groups. The B.Dm/Ma.Dm ratio
was able to compare even minimal changes in the cortical
w i d t ho ft h es u b t r o c h a n t e r i cr e g i o no ft h er a tf e m u ra m o n g
all groups. Although we did not see any signiﬁcant changes
between any of the groups concerning B.Dm, the mean
values of Ma.Dm were signiﬁcantly lower in both PTH-
treated groups compared to OVX animals. The mean values
of the B.Dm/Ma.Dm ratio were signiﬁcantly higher in both
PTH 5x/w rats (1.843) and PTH e2d rats (1.805) compared
to the OVX group (1.652). The PTH 5x/w rats also showed
a signiﬁcantly higher B.Dm/Ma.Dm ratio compared to the
sham animals (1.726) (Table 2).
These results in addition to the results of ﬂuorescence
microscopy could show useful information about endosteal
and periosteal bone remodeling (apposition bands) within
the cortical surface. The increased bone formation rate was
observed under PTH treatment in both groups mainly at
the endosteal side by ﬂuorescent microscopic analysis of
the cross sections from the proximal femur. The endosteum
seems here to be one of the targets of PTH with an
accelerate bone formation and a pronounced ﬁlling-in of
intracortical cavities with higher intensity for the PTH 5x/w
in comparison to PTH e2d rats (Figure 3).
4.Discussion
The paradoxical eﬀects of PTH on bone were ﬁrst described
by Selye in 1932. He observed that continuous intravenous
administration of PTH was able to elevate predominantly
t h eb o n er e s o r p t i o n[ 6]. In contrast, the intermittent admin-
istration of PTH mainly resulted in a stimulation of bone
formation, especially in the trabecular area [16]. In the
last several years, studies have emphasized the importance
of evaluating the eﬀects of this hormone in cortical areas
[16, 17].
Although many studies could conﬁrm the anabolic eﬀect
of PTH on bone, the question of which application frequen-
cies produce the best results is still controversial. Another
important question is in which skeletal sites (proximal tibia,
vertebral bodies, etc.) would we expect to see detectableJournal of Osteoporosis 5
Table 1: Study results. Body weight, mineral content, biomechanical test, and serum analysis of anabolic bone parameters.
SHAM OVX PTH 5x/w PTH e2d
Mean STD Mean STD Mean STD Mean STD
Body weight
Before OVX (g) 247.1 8.17 236.7 19.71 240.0 14.67 246.6 10.41
At the end of trial (g) 274.3a 15.91 341.0 23.64 341.4b 24.95 346.2b 32.48
Mineral content (after ashing) in left femurs (%) 49.68a 1.93 45.80b 1.68 49.54a 1.89 48.30a 1.41
Biomechanical test
Fmax (N) 187.0 20.81 169.3 25.38 194.1a 22.78 176.3 17.97
Stiﬀness (N/mm) 294.8a 68.19 230.2b 60.62 347.6ac 39.78 250.9 20.73
Yield load (N) 120.6a 28.67 86.96b 26.53 134.6a 25.77 110.3 9.6
Serum analysis
Osteocalcin (OC) (ng/mL) 14.59 7.51 17.83 6.67 32.55ab 6.26 37.43ab 9.63
Alkaline Phosphatase(AP) 40.90 21.62 59.83 21.62 59.54 15.04 74.27b 21.99
OVX (Ovariectomy), Fmax (maximal load).
The P value of the diﬀerence between treated and untreated animals was calculated using a one-way ANOVA. P values <. 05 were considered signiﬁcant.
aP<. 05 versus OVX, bP<. 05 versus sham, and cP<. 05 PTH 5x/w versus PTH e2d.
Table 2: Results of the histomorphometry analysis.
SHAM OVX PTH 5x/w PTH e2d
Mean STD Mean STD Mean STD Mean STD
Histomorphometry
Connectivity (N.Nd/mm2) 21.34a 5.52 11.91b 5.69 15.03b 2.86 19.10a 1.34
Trabecular area (Tb.Ar) (%) 66.85a 10.19 41.15b 9.5 81.54ab 8.96 73.38a 8.73
Trabecular width (Tb.Wi) (µm) 12.24 1.54 11.51 1.31 17.59abc 3.25 14.65a 1.31
Trabecular nodes (N.Nd) 58.33 15.56 37.60 26.56 42.90 12.5 54.57 11.65
Histomorphometry cortical subtrochanter
Bone diameter (B.Dm) (µm) 3228 203.6 3188 104.3 3217 75.42 3231 114.6
Marrow diameter (Ma.Dm) (µm) 1872 151.2 1933 102.4 1747a 87.39 1795a 99.61
Ratio (B.Dm/Ma.Dm) 1.726 0.073 1.652 0.058 1.843ab 0.068 1.805a 0.133
The P value of the diﬀerence between treated and untreated animals was calculated using a one-way ANOVA. P values <. 05 were considered signiﬁcant.
aP<. 05 versus OVX, bP<. 05 versus sham, and cP<. 05 PTH 5x/w versus PTH e2d.
positive antiosteoporotic eﬀects of this hormone [18]. The
trochanteric region of rat femur contains major trochanter,
minor trochanter, and tertius trochanter. The area between
these three trochanters was the region of interest in our
studies. The femur is one of the most important skeletal
sites in postmenopausal osteoporosis. Next to the femoral
neck fracture, the trochanteric fracture of the femur is one
of the most common fracture types in elderly women [6].
Thistypeoffracturepresentsasurgicalchallengeaswellasan
economicalproblem.Thispartoftheratfemurcontainsboth
trabecular and cortical bone, in contrast to the femoral shaft
[9]. Therefore, the intertrochanteric part of the femur seems
to be an important region to investigate the biomechanical
changes after therapy with antiosteoporotic substances like
the parathyroid hormone because PTH appears to inﬂuence
bothcorticalandtrabecularbonesurfaces [6,19].Hence,itis
important tolookfortherapy optionsand drugsthatprevent
such fractures in postmenopausal osteoporotic bone.
The intermittent administration of PTH gained more
importance in the last decade as a possible alternative for the
treatmentofosteoporosisandprophylaxisoffractures. Inthe
presentstudy,weinvestigatedtwotherapyoptionswithPTH.
We compared the anabolic eﬀect of PTH on the proximal
femurofOVXratsafterﬁveweeksofsubcutaneousinjections
(0.040/kg),ﬁvedaysaweek,orsubcutaneousinjectionsevery
2d a y s .
At the end of experiment, we observed a signiﬁcant
weight gain in OVX group compared to the sham group.
Neither the PTH 5x/w nor the PTH e2d treatment could
prevent the weight gain caused by OVX. Indeed, the sham
animals had the lowest weight gain of all of the rats.
When assessed by the breaking test, femurs of the PTH
5x/w treatment reached the strength level of sham rats.
Although the treatment with PTH e2d also led to better
mean values in the biomechanical test, the results were
not statistically signiﬁcant in comparison to OVX rats. The
changes observed in the biomechanical test were partially
evident when bones from PTH 5x/w- and PTH e2d-treated
rats were examined by histomorphometry.
In our opinion, the main reason for signiﬁcantly better
r e s u l t so fT b . A ri nP T H5 x / wr a t sw a st h ei m p r o v e m e n to f
trabecular thickness in these animals. The age-dependent6 Journal of Osteoporosis
OVX Sham
PTH 2ed PTH 5x/w
Figure 3: Analysis of ﬂuorescence apposition bands in transversal sections from the subtrochanteric region of rat femur. The sections (all
sections 15mm distalfrom femoralhead) were studied by ﬂuorescence microscopy. In the OVX group, we could mainlyobserve a periosteal
activity. Inthe shamgroup, onlya minimalperiosteal bone formationcouldbe seen.The PTHe2d-treated animalsshowedweakerendosteal
appositions in comparison to the PTH 5x/w animals.
study of Fridle et al., however, showed an increase in
trabecular number in younger rats, whereas older rats
demonstrated increases in trabecular thickness [3]. Another
study also showed similar age-related eﬀects of PTH [20].
Therapy with bone anabolic agents causes serum levels
of the bone formation markers OC and AP to increase, and
we observed similar results after PTH treatment. However,
we did not observe any statistically signiﬁcant diﬀerences
between the two PTH application paradigms in our study.
In case of AP, this could be due to the little sensitivity and
speciﬁcity of this bone formation marker.
Some studies have shown that after PTH treatment,
the addition of bone to the periosteal surface seems to
be responsible for a much greater contribution to bone
strength than bone added to the endosteal surface [19].
In contrast, the present work demonstrated increases in
the B.Dm/Ma.Dm ratio in both PTH-treated animals. This
ﬁnding was caused by a decrease in Ma.Dm rather than an
increase in B.Dm. In our study, the ﬂuorescence apposition
bands in the endosteal side of femoral cross sections
after PTH treatments underline this eﬀect. Although the
B.Dm/Ma.Dm-ratio was in the PTH 5x/w higher than PTH
e2d rats, the results were not statistically signiﬁcant. But in
our opinion, the higher dosages of PTH seem to have more
intensive anabolic eﬀect on the endosteal side of the cortical
surface. Additional experiments, however, are necessary to
underlinesucheﬀect. Itremainsunclear ,however ,ifthedose
of PTH plays any role. Komatsu et al. also showed that PTH
induced new bone formation at endocortical (endosteal)
surfaces [1]. Interestingly, in a fracture healing ratmodel, the
same authors found that PTH dose dependently (30µg/kg)
stimulated bone formation within the intramedullary cavity
[1].
In the ash test, higher total doses of 1–34 PTH induce a
better but not statistically signiﬁcant improvement on BMC,
reversing the eﬀects that the OVX has on this quantitative
determinant of bone strength.
Many of the measured parameters in our work did not
showanystatisticallysigniﬁcant diﬀerencesbetweenthePTH
5x/wandPTHe2dgroups,butthemeanvaluesinmostofthe
tests were slightly higher in the PTH 5x/w animals compared
tothePTH e2danimals. Inour opinion,theantiosteoporotic
eﬀects of PTH 5x/w seem to be slightly stronger than PTH
e2d treatment although we saw onlyin Tb.Wi and in stiﬀness
statistically signiﬁcant diﬀerences.
The exact signaling pathways of the anabolic eﬀect of
PTH are not clear, but the pathways activated after PTH
treatment determine whether this hormone has catabolicJournal of Osteoporosis 7
or anabolic actions [21]. The parathyroid hormone (PTH)
stimulates the processes that lead to bone formation prior
to stimulating the pathways associated with bone resorption.
The “window” between both of these eﬀects is not clear
[22]. Rubin and Bilezikian showed that the bone formation
markers reached a maximum level within a few days after
PTH treatment, whereas the bone resorption parameters
had the maximum level after approximately 3 weeks [21,
22]. We believe that during these three weeks between the
maximal anabolic and maximal catabolic phases of PTH,
named “anabolic window” by Rubinand Bilezikian,diﬀerent
PTH application frequencies could lead to an improvement
of bone strength; however, this would probably occur with
diﬀerent intensities. It is important to mention that the
half-life of PTH after a single application as well as the
dose and skeletal site where the anabolic eﬀect of PTH is
investigated are important aspects that play critical roles in
determining the eﬀects of PTH. Therefore, future investiga-
tions should evaluate the time- and dose-dependent changes
of the trochanteric region after PTH therapy. Furthermore,
additional experiments should be performed in animals of
diﬀerent ages and in male rats.
5.Conclusions
The trochanteric region of the rat femur is an important
skeletal site for osteoporosis studies because of its high clini-
cal relevance. The present study showed that treatment with
PTH 5x/w and PTH 2ed both improved the biomechanical
and histomorphometric propertiesand partially reversed the
eﬀects of OVX in the trochanteric region of the rat femur.
Under conditions presented in our study, the anabolic eﬀect
of PTH 5x/w seems to be slightly stronger than PTH e2d
therapy, but the main signiﬁcant changes were observed
concerning elasticity and Tb.wi. Further experiments are
needed to determine which form of PTH therapy options
is able to eﬀectively prevent trochanteric fractures. Thus,
futurestudiesrelatedtodose-andtime-relatedinvestigations
should be conducted.
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